Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease
- Conditions
- Atypical Hemolytic Uraemic Syndrome
- Registration Number
- NCT00930423
- Lead Sponsor
- University Hospital, Ghent
- Brief Summary
Atypical hemolytic uraemic syndrome is caused by defects in the regulating factors in the alternative pathway of the complement system. Triggering can cause an uncontrolled complement activation with endothelial damage and thrombotic micro-angiopathy, especially in the kidneys. This can result in endstage renal failure. Complement activation during hemodialysis has been described as a result of contact between blood and the dialysis membrane. Our hypothesis is that patients with atypical hemolytic uraemic syndrome have a stronger complement activation during hemodialysis than patients with another underlying kidney disease. This could be a reason to treat patients with endstage renal failure due to atypical hemolytic uraemic syndrome preferentially with peritoneal dialysis instead of hemodialysis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
- cases: endstage renal failure due to atypical hemolytic uraemic syndrome treated with hemodialysis.
- controls: endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method C3a-des-Arg measuring (as a marker of activation). at time 0, at 15 minutes, at 60 minutes and at 180 minutes white blood cell count before and after 15 minutes of hemodialysis
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital Ghent
🇧🇪Ghent, Belgium